Increasing Incidence of Hip Fracture in Chiang Mai, Thailand

Wongtriratanachai, Prasit; Luevitoonvechkij, Sirichai; Vaseenon, Tanawat; Songpatanasilp, Thawee; Rojanasthien, S.

doi:10.1016/j.jocd.2009.03.041

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A common cause of fracture in osteoporosis subjects is a fall from a standing height or less; 90% of hip fractures result from a fall . Therefore, falls risk reduction is an important component of primary and secondary fragility fracture prevention strategies, usually delivered via multidisciplinary approaches .…”

Section: Introductionmentioning

confidence: 99%

A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab

Chotiyarnwong

McCloskey

Eastell

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Recent studies suggest that the RANK/RANKL system impacts muscle function and/or mass. In the pivotal placebo‐controlled fracture trial of the RANKL inhibitor denosumab in women with postmenopausal osteoporosis, treatment was associated with a lower incidence of non‐fracture‐related falls (p = 0.02). This ad hoc exploratory analysis pooled data from five placebo‐controlled trials of denosumab to determine consistency across trials, if any, of the reduction of fall incidence. The analysis included trials in women with postmenopausal osteoporosis and low bone mass, men with osteoporosis, women receiving adjuvant aromatase inhibitors for breast cancer, and men receiving androgen deprivation therapy for prostate cancer. The analysis was stratified by trial, and only included data from the placebo‐controlled period of each trial. A time‐to‐event analysis of first fall and exposure‐adjusted subject incidence rates of falls were analyzed. Falls were reported and captured as adverse events. The analysis comprised 10,036 individuals; 5030 received denosumab 60 mg subcutaneously once every 6 months for 12 to 36 months and 5006 received placebo. Kaplan–Meier estimates showed an occurrence of falls in 6.5% of subjects in the placebo group compared with 5.2% of subjects in the denosumab group (hazard ratio = 0.79; 95% confidence interval 0.66–0.93; p = 0.0061). Heterogeneity in study designs did not permit overall assessment of association with fracture outcomes. In conclusion, denosumab may reduce the risk of falls in addition to its established fracture risk reduction by reducing bone resorption and increasing bone mass. These observations require further exploration and confirmation in studies with muscle function or falls as the primary outcome. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research..

show abstract

Section: Introductionmentioning

confidence: 99%

A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab

Chotiyarnwong

McCloskey

Eastell

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…It was found that 80% of hip fractures occurred in people over 70 years. Increased Hip fracture incidence in Thailand in 2006, 2025 and 2550 are expected to equal 23,426, 34,246 and 56,443 cases, respectively [6] .…”

Section: Epidemiology Of Osteoporosis and Osteoporotic Fractures In Tmentioning

confidence: 99%

“… Female aged over 65 years and male aged over 70 years [6] . Early menopause (before 45 years including bilateral oophorectomy).…”

Section: Measurement Of Bone Densitymentioning

confidence: 99%

“…Female aged over 65 years and male aged over 70 years [6].Early menopause (before 45 years including bilateral oophorectomy).Hypoestrogenism for more than 1 consecutive year before menopause (receiving GnRH, prolonged intensive exercise, chronic illness) with the exception of pregnancy and breastfeeding.Prolonged glucocorticoid administration (daily prednisolone 7.5 mg or equivalent for at least 3 consecutive months).History of fraternal or maternal hip fracture [25].Menopausal women with body mass index less than 20 kg/m 2 [26].Menopausal women with decreased height of at least 4 cm [27].Female receiving treatment by aromatase inhibitors [28] or male receiving treatment by androgen deprivation therapy [29].Radiographic osteopenia and/or vertebral deformity by X-ray [9].History of fracture from low-energy injury [30].FRAX ® assessment for risk of fracture, specific for Thai population, with non BMD approach result showing 10-year probability of fracture in intermediate risk [31].Rated in intermediate group by OSTA score [11], KKOS score [12] or risk from nomogram (probability) is equal to or more than 0.3 for menopausal women [32].…”

Section: Measurement Of Bone Densitymentioning

confidence: 99%

See 1 more Smart Citation

Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis

Songpatanasilp

Sritara

Kittisomprayoonkul

et al. 2016

Osteoporosis and Sarcopenia

View full text Add to dashboard Cite

The adjusted incidence rate of hip fracture in Thailand has increased more than 31% from 1997 to 2006. Mortality and morbidity after hip fracture are also high. One year mortality after a hip fracture has increased from 18% in 1999 to 21% in 2007. The Thai Osteoporosis Foundation (TOPF) developed the first Clinical Practice Guideline (CPG) in 2002 and keeps updating the CPG since then. This latest version of the CPG is our attempt to provide comprehensive positional statement on the diagnosis, prevention and treatment of osteoporosis in Thailand. The study group who revised this position statement contains experts from the TOPF, Four Royal Colleges of Thailand, includes the Orthopaedic Surgeons, Gynecologists and Obstetricians, Physiatrists, Radiologists and 2 Associations of Endocrinologists and Rheumatologists which have involved in the management of patients with osteoporosis.

show abstract

“…Another study conducted in Chiang Mai, Thailand (P. Wongtriratanachai et al.) found that first year mortality in hip fracture is approximately 18–20% [4] . A study conducted in Finland (E. Lonnroos et al.)…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Police General Hospital's Fracture Liaison Service (PGH's FLS): The first study of a Fracture Liaison Service in Thailand

Amphansap

Stitkitti

Dumrongwanich

2016

Osteoporosis and Sarcopenia

View full text Add to dashboard Cite

ObjectivesThe purpose of the study was to assess the effectiveness of the Fracture Liaison service (FLS) in preventing secondary fracture and decreasing 1-year mortality rate after osteoporotic hip fracture, in patients at Police General Hospital, Bangkok, Thailand.MethodsA prospective cohort study was conducted. We studied male and female patients, 50 years of age and older, who presented with a fragility fracture around the hip due to low energy trauma and were admitted to Police General Hospital, participating in PGH's Liaison service from April 1, 2014–March 30, 2015. The sample size was 75 patients, with a follow up time of 1 year. The data from this study was compared with that of a previous study done by Tanawat A. et al. [9] prior to commencement of the FLS project.ResultsAfter a follow up period of 1 year, the mortality rate was measured to be 10.7% and there was no evidence of secondary fragility fracture. Post-injury bone mineral density follow up and osteoporotic medication treatment rates were 48% and 80%, respectively. Patients who participated in the project were found to have a decreasing rate of secondary fracture from 30% to 0% (P < 0.0001), an increasing post-injury BMD follow up rate from 28.3% to 48% (P = 0.0053), and an increase in post-injury osteoporotic medication administration rate from 40.8% to 80% (P = 0.0148), all with statistical significance. However, the 1-year mortality rate was not significant (P = 0.731) when compared to the previous study.ConclusionsPatients with recent hip fractures participating in the Fracture Liaison service had a significantly higher post-injury BMD follow up and osteoporotic medication administration rates. This resulted in a lower risk of secondary fracture than those who did not participate in the Fracture Liaison service at a follow up time of one year.

show abstract

Increasing Incidence of Hip Fracture in Chiang Mai, Thailand

Cited by 4 publications

References 0 publications

A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab

A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab

Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis

Evaluation of Police General Hospital's Fracture Liaison Service (PGH's FLS): The first study of a Fracture Liaison Service in Thailand

Contact Info

Product

Resources

About